Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program HT9402-26-Q-9104
Summary
AI-generated · Jan 10, 2026A federal procurement seeks quotes from industry to supply pharmaceutical agents within drug classes identified for placement on the Uniform Formulary (UF). Quotes will support the P&T Committee’s evaluation of relative clinical and cost effectiveness, determining which agents are added to the UF and how they are classified for cost sharing (generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary). Based on UF decisions, UF Blanket Purchase Agreements (BPA) and Uniform Formulary Additional Discount Program Agreements (ADP) may be awarded. The RFQ package (including UF BPA and UF ADP appendices) contains instructions, deadlines, and points of contact.
The upcoming P&T Committee review will examine four newly approved drugs: Aqvesme (replacement enzymes), Forzinity (miscellaneous metabolic agents), Omlonti (glaucoma), and Voyxact (nephrology). The RFQ contains the required appendices and guidance for bidding. A pre-quotation teleconference is scheduled, and responses to clinical questions must be submitted by email to the RFQ POC in accordance with the instructions in Part 2.3 (PQC contact) and Part 3.4 (clinical questions), by the deadline stated in the RFQ.
The Department of Defense (DoD) is required by law (10 U.S.C. 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2026 newly approved drugs will be reviewed: a. Aqvesme - Metabolic Agents-Miscellaneous - Replacement Enzymes b. Forzinity - Metabolic Agents-Miscellaneous - NA c. Omlonti - Glaucoma Agents - NA d. Voyxact - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9104. Pre-quotation teleconference is on January 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
From Solicitation posted on Jan 09, 2026Notice history
1Details
Award Information
Not yet awarded